A. Marini

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2012, British Journal of Cancer.

Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors

A. Markoe, N. Savaraj, L. Feun, 2007, Journal of Neuro-Oncology.

Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

N. Savaraj, L. Feun, M. Modiano, 2002, Cancer Chemotherapy and Pharmacology.

Cyclosporine A, Alpha-Interferon and Interleukin-2 Following Chemotherapy with BCNU, DTIC, Cisplatin, and Tamoxifen: A Phase II Study in Advanced Melanoma

N. Savaraj, L. Feun, F. Moffat, 2005, Cancer investigation.

Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial

E. Schiff, N. Savaraj, L. Feun, 2003, Journal of Cancer Research and Clinical Oncology.

Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma.

N. Savaraj, L. Feun, J. Bomalaski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma

N. Savaraj, L. Feun, J. Hurley, 2000 .

Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM).

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2010 .

Phase II Trial of Paclitaxel and Dacarbazine with Filgrastim Administration in Advanced Malignant Melanoma

N. Savaraj, L. Feun, J. Hurley, 2002, Cancer Investigation.